{"id":"stem-cell-mobilization-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bone pain"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process is typically achieved through the administration of granulocyte-colony stimulating factor (G-CSF) or other mobilizing agents, which work by binding to specific receptors on the surface of stem cells and triggering their release into the circulation. The mobilized stem cells can then be collected from the blood and used for transplantation or other therapeutic purposes.","oneSentence":"Stem Cell Mobilization Therapy involves the use of certain medications to stimulate the release of stem cells from the bone marrow into the bloodstream.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:34.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autologous stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT01212055","phase":"","title":"Apheresis of Patients With Immunodeficiency","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-08","conditions":"LAD-1, DOCK8, GATA2 Deficancy","enrollment":7},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT02015013","phase":"PHASE2","title":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-15","conditions":"Idiopathic CD4-Positive, T-Lymphocytopenia","enrollment":40},{"nctId":"NCT03520647","phase":"PHASE2","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2019-02-19","conditions":"Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":56},{"nctId":"NCT06876363","phase":"PHASE1, PHASE2","title":"Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"Ensoma","startDate":"2025-08-05","conditions":"X-Linked Chronic Granulomatous Disease","enrollment":15},{"nctId":"NCT03587272","phase":"PHASE2","title":"Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Robert Nickel","startDate":"2018-04-17","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT05561751","phase":"PHASE2","title":"Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"GPCR Therapeutics, Inc.","startDate":"2023-02-13","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT07392970","phase":"PHASE2","title":"Motixafortide for MRD Sensitization in AML","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Acute Myeloid Leukemia, Measurable Residual Disease","enrollment":10},{"nctId":"NCT05421416","phase":"PHASE2","title":"Loratadine for the Prevention of G-CSF-related Bone Pain","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-11-28","conditions":"Stem Cell Transplant Complications","enrollment":78},{"nctId":"NCT07376460","phase":"","title":"Proteomic and Biological Characterisation of Plasma for the Study of Changes Following Ovarian Reactivation Treatment","status":"NOT_YET_RECRUITING","sponsor":"Instituto Valenciano de Infertilidad, IVI Alicante","startDate":"2026-02","conditions":"Poor Ovarian Response, Ovarian Reactivation","enrollment":10},{"nctId":"NCT03617731","phase":"PHASE3","title":"Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2018-10-18","conditions":"Multiple Myeloma","enrollment":662},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT07376122","phase":"NA","title":"Pilot Study of Robotic Spinal Mobilization in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Pacla Medical Limited","startDate":"2026-03-09","conditions":"Parkinson's Disease (PD)","enrollment":30},{"nctId":"NCT06442761","phase":"PHASE1","title":"SCD Stem Cell Mobilization and Apheresis Using Motixafortide","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-11-14","conditions":"Sickle Cell Disease","enrollment":15},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT03246529","phase":"PHASE3","title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioLineRx, Ltd.","startDate":"2018-03-23","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT07341022","phase":"PHASE1, PHASE2","title":"STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE","status":"NOT_YET_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2026-06-01","conditions":"Sickle Cell Disease","enrollment":12},{"nctId":"NCT03897361","phase":"PHASE1, PHASE2","title":"Stem Cell Gene Therapy for Cystinosis","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-07-08","conditions":"Lysosomal Storage Diseases, Cystinosis","enrollment":6},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT01174108","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-12-10","conditions":"Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)","enrollment":120},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT07310823","phase":"NA","title":"Mangement of Cervicogenic Headache by Maual Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"Cairo University","startDate":"2025-12-20","conditions":"Cervicogenic Headache, Neck Pain Musculoskeletal","enrollment":57},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":"RUNX1 Familial Platelet Disorder","enrollment":4},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT03317899","phase":"PHASE2","title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-10-12","conditions":"Non-Hodgkin's Lymphoma, Plasma Cell Myeloma","enrollment":77},{"nctId":"NCT06514508","phase":"PHASE3","title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","startDate":"2025-12-01","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT05900401","phase":"PHASE1, PHASE2","title":"Delayed Tolerance Through Mixed Chimerism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-10-01","conditions":"Kidney Failure, Kidney Transplant; Complications, Chimera","enrollment":20},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT03618550","phase":"PHASE2","title":"Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-01","conditions":"Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma","enrollment":257},{"nctId":"NCT02223208","phase":"PHASE1, PHASE2","title":"Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-09","conditions":"Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic T-cell Lymphoma (AITL)","enrollment":89},{"nctId":"NCT07188090","phase":"PHASE2","title":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-16","conditions":"Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma","enrollment":100},{"nctId":"NCT07254793","phase":"PHASE1","title":"Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-28","conditions":"Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL)","enrollment":94},{"nctId":"NCT02570542","phase":"PHASE2","title":"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-10","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":59},{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT06507514","phase":"PHASE1","title":"Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-04-01","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT07236151","phase":"PHASE2","title":"Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-02-24","conditions":"Large B-cell Lymphoma, CAR T Cell Therapy, Auto Stem Cell Transplant","enrollment":23},{"nctId":"NCT07233369","phase":"NA","title":"Effect of Myofascial Release on Pain, Grip Strength, Manual Dexterity, and Quality of Life in Late-Term Rehabilitation of Hand Flexor Tendon Repairs","status":"NOT_YET_RECRUITING","sponsor":"Hasan Kalyoncu University","startDate":"2025-11-30","conditions":"Hand Flexor Tendon, Facial Mobilization, Exercise","enrollment":42},{"nctId":"NCT07233343","phase":"NA","title":"Effects of Fascial Mobilization Therapy in Patients With Carpal Tunnel Syndrome","status":"COMPLETED","sponsor":"Hasan Kalyoncu University","startDate":"2024-08-10","conditions":"Carpal Tunnel Syndrome (CTS), Fascial Mobilization, Post Partum","enrollment":30},{"nctId":"NCT03818763","phase":"PHASE1","title":"Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-04-29","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT05343572","phase":"EARLY_PHASE1","title":"Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium","status":"RECRUITING","sponsor":"Hugh Taylor","startDate":"2023-11-01","conditions":"Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure","enrollment":90},{"nctId":"NCT03125642","phase":"PHASE2","title":"Auto Stem Cell Transplant for Lymphoma Patients","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-20","conditions":"Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT01508312","phase":"PHASE2","title":"Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-01-05","conditions":"Hodgkin's Lymphoma","enrollment":66},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT01815749","phase":"PHASE1","title":"Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2013-10-08","conditions":"Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","enrollment":30},{"nctId":"NCT05517213","phase":"NA","title":"High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2022-09-01","conditions":"Multiple Myeloma","enrollment":62},{"nctId":"NCT05632380","phase":"PHASE1, PHASE2","title":"ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-07-14","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03837483","phase":"PHASE3","title":"A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Telethon","startDate":"2019-01-21","conditions":"Wiskott-Aldrich Syndrome","enrollment":10},{"nctId":"NCT07186179","phase":"","title":"Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-10-01","conditions":"Diamond Blackfan Anemia","enrollment":10},{"nctId":"NCT07179666","phase":"NA","title":"Comparing Neural Mobilization and Traditional Physiotherapy in Plantar Fasciitis Patients","status":"NOT_YET_RECRUITING","sponsor":"Gulf Medical University","startDate":"2025-09-12","conditions":"Plantar Fasciitis","enrollment":12},{"nctId":"NCT03055247","phase":"PHASE2","title":"Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2015-11-06","conditions":"Chronic Granulomatous Disease X-linked (X-CGD)","enrollment":3},{"nctId":"NCT03664830","phase":"PHASE1","title":"Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-09-19","conditions":"Sickle Cell Disease","enrollment":5},{"nctId":"NCT02678533","phase":"PHASE1, PHASE2","title":"Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-02-10","conditions":"Fanconi Anemia","enrollment":4},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT05844527","phase":"PHASE2","title":"Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients","status":"COMPLETED","sponsor":"MedRegen LLC","startDate":"2023-11-20","conditions":"Wound of Skin, Abdominal Wound","enrollment":10},{"nctId":"NCT06547112","phase":"PHASE1","title":"A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2024-10-31","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03093844","phase":"NA","title":"Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-10-12","conditions":"Hematologic Disorders","enrollment":150},{"nctId":"NCT05835726","phase":"","title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-01-01","conditions":"Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation","enrollment":188},{"nctId":"NCT07117305","phase":"PHASE1, PHASE2","title":"CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou University","startDate":"2025-09-01","conditions":"CD7+ Lymphoma, T Cell Lymphoma","enrollment":38},{"nctId":"NCT05618301","phase":"PHASE1","title":"Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-07-07","conditions":"Sickle Cell Disease","enrollment":10},{"nctId":"NCT07106710","phase":"PHASE2","title":"ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-10","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":30},{"nctId":"NCT07106684","phase":"PHASE2","title":"ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-10","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT03333486","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-12-07","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia","enrollment":31},{"nctId":"NCT06802315","phase":"PHASE2","title":"Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-02-04","conditions":"Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase","enrollment":38},{"nctId":"NCT06017869","phase":"PHASE2","title":"Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)","status":"RECRUITING","sponsor":"Minovia Therapeutics Ltd.","startDate":"2023-07-31","conditions":"Mitochondrial Diseases, Pearson Syndrome","enrollment":6},{"nctId":"NCT05470777","phase":"PHASE2","title":"CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-01-19","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":37},{"nctId":"NCT02220985","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":84},{"nctId":"NCT06997471","phase":"PHASE1","title":"Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"Francisco Hernández Oliveros","startDate":"2025-06","conditions":"Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection","enrollment":10},{"nctId":"NCT06228781","phase":"NA","title":"Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-12-01","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT06986382","phase":"PHASE1, PHASE2","title":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-07","conditions":"Crohn Disease","enrollment":14},{"nctId":"NCT05015920","phase":"NA","title":"A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants","status":"COMPLETED","sponsor":"Shanghai BDgene Co., Ltd.","startDate":"2021-07-10","conditions":"Hematologic Diseases","enrollment":2},{"nctId":"NCT05294055","phase":"PHASE2","title":"Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-04-26","conditions":"Multiple Myeloma, Lymphoma","enrollment":120},{"nctId":"NCT05124288","phase":"","title":"Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways","status":"RECRUITING","sponsor":"Ciceri Fabio","startDate":"2022-07-18","conditions":"Acute Myeloid Leukemia, in Relapse","enrollment":500},{"nctId":"NCT06965985","phase":"NA","title":"Comparison of the Effectiveness of Mulligan Mobilization and Myofascial Release Technique in Patients With Lateral Epicondylitis","status":"RECRUITING","sponsor":"Konya Beyhekim Training and Research Hospital","startDate":"2025-01-01","conditions":"Lateral Epicondylitis (Tennis Elbow)","enrollment":114},{"nctId":"NCT06955858","phase":"NA","title":"Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-30","conditions":"Hematopoietic Stem Cell Mobilization","enrollment":60},{"nctId":"NCT01318317","phase":"PHASE1, PHASE2","title":"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-09-19","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":8},{"nctId":"NCT06938334","phase":"PHASE1, PHASE2","title":"A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Altheia Science","startDate":"2025-08-15","conditions":"Diabetes, Type I","enrollment":15},{"nctId":"NCT01661881","phase":"PHASE2","title":"Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-08-16","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT03755414","phase":"PHASE1","title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-09-04","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes","enrollment":55},{"nctId":"NCT05432310","phase":"PHASE1, PHASE2","title":"Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-01-04","conditions":"Adenosine Deaminase Severe Combined Immune Deficiency","enrollment":20},{"nctId":"NCT03442673","phase":"PHASE2","title":"Chemotherapy and G-CSF for Mobilization","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-09-17","conditions":"Multiple Myeloma","enrollment":137},{"nctId":"NCT01186224","phase":"NA","title":"Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2010-05","conditions":"Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoma","enrollment":60},{"nctId":"NCT01050036","phase":"NA","title":"Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-01-11","conditions":"Leukemia, Myeloid","enrollment":20},{"nctId":"NCT02140554","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Genetix Biotherapeutics Inc.","startDate":"2015-02-02","conditions":"Sickle Cell Disease","enrollment":54},{"nctId":"NCT02105766","phase":"PHASE2","title":"Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-04-21","conditions":"Sickle Cell Disease, Thalassemia, Stem Cell Transplantation","enrollment":56},{"nctId":"NCT04860726","phase":"NA","title":"Myofascial Release and Joint Mobilization Therapy in Non-Specific Low Back Pain","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2021-04-25","conditions":"Low Back Pain","enrollment":84},{"nctId":"NCT04561947","phase":"NA","title":"Treatment of Gingival Recessions with Connective Tissue or Concentrated Growth Factor Membrane Using Tunnel Technique","status":"COMPLETED","sponsor":"Bulent Ecevit University","startDate":"2017-10-01","conditions":"Gingival Recession","enrollment":40},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":"Systemic Scleroderma","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chemomobilization","Hematopoietic Stem Cell Mobilization","Mobilization Therapy","Stem-cell mobilization"],"phase":"phase_3","status":"active","brandName":"Stem Cell Mobilization Therapy","genericName":"Stem Cell Mobilization Therapy","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stem Cell Mobilization Therapy is a treatment approach that involves the use of various modalities, including filgrastim and rituximab, to mobilize stem cells in conditions such as Follicular Lymphoma, Lymphoma, and Multiple Sclerosis. The therapy is based on the mechanism of removing necrotic tissue, which is facilitated by the enzyme activity of certain agents, such as bromelain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}